https://www.selleckchem.com/pr....oducts/GSK429286A.ht
No significant differences were noted in the incidence of serious adverse events (SAEs) after tofacitinib+MTX, mavrilimumab+MTX, or placebo+MTX. In patients with RA showing inadequate DMARD response, mavrilimumab 150 mg+MTX and mavrilimumab 100 mg+MTX, followed by tofacitinib 10 mg+MTX and tofacitinib 5 mg+MTX, were the most efficacious interventions and were not associated with a significant risk of SAEs. In patients with RA showing inadequate DMARD response, mavrilimumab 150 mg+MTX and mavrilimumab 100 mg+MTX, followed by tofacitin
Like
Comment
Share
